Cell-free DNA

Global Non-Invasive Prenatal Testing (NIPT) Market Report 2022-2027: Industry Trends, Growth, Insight, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, April 4, 2022

However, the lack of established outcomes has cast doubt on the demand for these tests amidst the pandemic.

Key Points: 
  • However, the lack of established outcomes has cast doubt on the demand for these tests amidst the pandemic.
  • Furthermore, the market expansion is expected to be fuelled by innovations in existing tests in advanced functionality, improved chemistry, and bioinformatics analysis.
  • Natera announced in December 2020 that its non-invasive prenatal testing (NIPT) would be covered by the most extensive U.S. health plan, Aetna, for all pregnancies.
  • Compared to hospitals, diagnostic laboratories are equipped with cutting-edge equipment that allows for safe and successful prenatal testing.

Natera to Participate in the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 23, 2021

SAN CARLOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021 at 11:10 a.m. PT (2:10 p.m.

Key Points: 
  • SAN CARLOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021 at 11:10 a.m. PT (2:10 p.m.
  • Mike Brophy, Chief Financial Officer, will provide an overview of the company and discuss recent business activities, followed by a question and answer session.
  • Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw.
  • The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health.

Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021

SAN CARLOS, Calif., Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th Annual J.P.MorganHealthcare Conference on Tuesday, Jan. 12, 2021 at 12:40 p.m. PT (3:40 p.m.

Key Points: 
  • SAN CARLOS, Calif., Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th Annual J.P.MorganHealthcare Conference on Tuesday, Jan. 12, 2021 at 12:40 p.m. PT (3:40 p.m.
  • Access to the live webcast and subsequent archived presentation will be available at investor.natera.com.
  • Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw.
  • Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.

Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

Retrieved on: 
Thursday, November 12, 2020

SAN CARLOS, Calif., Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, at 1:30 p.m. PT (4:30 p.m.

Key Points: 
  • SAN CARLOS, Calif., Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, at 1:30 p.m. PT (4:30 p.m.
  • Mike Brophy, Chief Financial Officer, will discuss Natera's latest developments and business activities.
  • Natera is a pioneer and global leader in cell-free DNA testing.
  • Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California.

Cell-Free DNA (cfDNA) Testing Market Size Worth USD 22.41 Billion by 2027 | CAGR of 26.2%: Emergen Research

Retrieved on: 
Tuesday, October 20, 2020

VANCOUVER, BC, Oct. 20, 2020 /PRNewswire/ -- The Global Cell-Free DNA (cfDNA) Testing Market is forecast to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research.

Key Points: 
  • VANCOUVER, BC, Oct. 20, 2020 /PRNewswire/ -- The Global Cell-Free DNA (cfDNA) Testing Market is forecast to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research.
  • Moreover, increasing investments by governments to implement advanced therapeutic technology in hospitals is also expected to boost the market during the forecast period.
  • Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Global Cell-Free DNA (cfDNA) Testing Market in 2019.
  • To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/cell-free-dna-market
    Emergen Research has segmented the Global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:

Cell-Free DNA (cfDNA) Testing Market Size Worth USD 22.41 Billion by 2027 | CAGR of 26.2%: Emergen Research

Retrieved on: 
Tuesday, October 20, 2020

- Market Size USD 3.80 billion in 2019, Market Growth - CAGR of 26.2%, Market Trends Rise in the use of Cell-Free DNA (cfDNA) Testingto treat chromosomal disorders.

Key Points: 
  • - Market Size USD 3.80 billion in 2019, Market Growth - CAGR of 26.2%, Market Trends Rise in the use of Cell-Free DNA (cfDNA) Testingto treat chromosomal disorders.
  • VANCOUVER, BC, Oct. 20, 2020 /PRNewswire/ -- The Global Cell-Free DNA (cfDNA) Testing Market is forecast to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research.
  • Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Global Cell-Free DNA (cfDNA) Testing Market in 2019.
  • To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/cell-free-dna-market
    Emergen Research has segmented the Global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:

Streck Cell-Free DNA BCT® receives U.S. FDA De Novo clearance

Retrieved on: 
Friday, September 11, 2020

LA VISTA, Neb., Sept. 11, 2020 /PRNewswire/ --Streck Cell-Free DNA BCT received U.S. Food and Drug Administration De Novo clearance for In Vitro Diagnostic use when paired with the Guardant360 CDx liquid biopsy assay.

Key Points: 
  • LA VISTA, Neb., Sept. 11, 2020 /PRNewswire/ --Streck Cell-Free DNA BCT received U.S. Food and Drug Administration De Novo clearance for In Vitro Diagnostic use when paired with the Guardant360 CDx liquid biopsy assay.
  • "Streck is excited about this milestone for Cell-Free DNA BCT," said Product Manager Joel Lechner.
  • "We have always known that Cell-Free DNA BCT is the best tube for customers who are concerned about pre-analytical variation, but De Novo IVD status solidifies Cell-Free DNA BCT as a truly novel collection tube."
  • Cell-Free DNA BCT was the first tube on the market focusing on cell-free DNA in plasma, more than 10 years ago.

Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Thursday, September 10, 2020

SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept. 14, 2020, at 9:00 a.m. PT (12:00 p.m.

Key Points: 
  • SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept. 14, 2020, at 9:00 a.m. PT (12:00 p.m.
  • Steve Chapman, Chief Executive Officer, and Mike Brophy, Chief Financial Officer, will discuss Natera's latest developments and business activities.
  • Natera is a pioneer and global leader in cell-free DNA testing.
  • Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California.